Physician profile
Aye Thet
NPI 1124518477
$2,041.98
in general payments reported to CMS, 2019-2025
22 companies · $564 in 2025
The $564 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.15 · 2023: $77.57 · 2024: $1,383 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,481 · Education: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.74 |
| Education | $418.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $356.92 | 2023-2025 | Calquence, Imfinzi, Lynparza |
| Alexion Pharmaceuticals, INC. | $324.43 | 2021-2024 | Soliris |
| Sobi, INC | $225.90 | 2024 | |
| Genentech USA, INC. | $183.49 | 2024-2025 | Columvi, Lunsumio, Tecentriq |
| Jazz Pharmaceuticals INC. | $143.43 | 2024 | |
| Eisai INC. | $103.28 | 2024 | |
| Exelixis INC. | $93.01 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $66.94 | 2024 | Onivyde |
| Genzyme Corporation | $49.45 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.72 | 2025 | Iclusig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $38.03 | 2025 | |
| Janssen Biotech, INC. | $37.71 | 2024-2025 | Rybrevant |
| Pfizer INC. | $37.22 | 2025 | |
| Abbvie INC. | $34.42 | 2025 | |
| Blueprint Medicines Corporation | $31.87 | 2023 | Ayvakit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $27.62 | 2025 | Jakafi, Niktimvo |
| Genmab U.S., INC. | $27.44 | 2025 | Tivdak |
| Adc Therapeutics America, INC. | $24.10 | 2025 | |
| Geron Corporation | $20.24 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $19.83 | 2025 | Lynozyfic |
| Merck Sharp & Dohme LLC | $16.10 | 2025 | Lynparza, Keytruda, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $14.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aye Thet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.